Magnesium L-Threonate

Magnesium L-threonate is not worth the price premium for most people. It is the only form shown to raise brain magnesium in animals, but human evidence for cognition and sleep is thin: the only larger RCT (Zhang 2022, n=109) tested a compound formula with phosphatidylserine and vitamins, not Magtein alone, and the 2024 Hausenblas sleep RCT failed its primary endpoint. At roughly 10x the cost of glycinate, and with only ~144mg elemental magnesium per clinical dose, it is an expensive bet on an early and complicated evidence base.

The case for this form begins with an MIT study showing that magnesium L-threonate uniquely crosses the blood-brain barrier in animals, raising brain magnesium levels where other forms did not. Magnesium plays a critical role in how neurons form and strengthen connections, so a form that reaches the brain could have unique cognitive benefits.

The human evidence is more modest. A pilot trial of 44 older adults (Liu et al. 2016) showed cognitive improvements over 12 weeks. A larger trial of 109 adults (Zhang et al. 2022) found cognitive improvements, but critically this study tested a compound formula combining Magtein with phosphatidylserine, vitamin C, and vitamin D3 - not isolated magnesium L-threonate. Notably, older participants in the Zhang trial derived more pronounced cognitive benefits than younger cohorts, supporting the hypothesis that age-related intracellular magnesium depletion amplifies the need for CNS delivery. It is impossible to attribute the benefit to Magtein alone from this trial. A 2024 sleep-focused RCT (Hausenblas et al., PMID 39252819, n=80) found improved secondary endpoints - post-awakening mood, daytime mental alertness, reduced resting heart rate, and increased heart rate variability (suggesting improved parasympathetic tone) - but failed its primary endpoint (Insomnia Severity Index), with both placebo and treatment groups showing massive sleep improvements, consistent with a pronounced placebo effect. A 2021 meta-analysis of oral magnesium for insomnia (Mah & Pitre, PMID 33865376) found magnesium reduced sleep onset latency by 17.4 minutes but showed no significant improvement in total sleep time; evidence was graded "low to very low" quality across all trials. The evidence is still early and complicated by confounded study designs.

Clinical consensus is appropriately conservative: Magnesium L-Threonate is recognized as mechanistically elegant and safe, showing promise for age-related cognitive decline and working memory in older adults. However, the absence of direct head-to-head human trials comparing threonate against glycinate or other forms means the claimed brain superiority remains theoretical. For systemic anxiety, sleep, and muscle relaxation, magnesium bisglycinate remains the preferred clinical form - glycine itself acts as an independent inhibitory neurotransmitter independent of the magnesium.

Critically: magnesium L-threonate is not a substitute for other magnesium forms if you are deficient. Its elemental magnesium content is low (about 7-8% by weight), so 2g Magtein delivers only ~144mg elemental magnesium. If your goal is correcting deficiency, treating sleep problems, reducing blood pressure, or relieving muscle cramps, glycinate or citrate are far more cost-effective. Magnesium L-threonate is specifically for people who want to optimize brain magnesium levels and are already meeting their general magnesium needs. The evidence is promising but the category is still early.